Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-pVAC-SARS-CoV-2 peptide vaccine in adults with B-cell/antibody deficiency
2021-001070-38Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of CoVac-1 in coronavirus disease 2019 (COVID-19) and B cell deficiency, sponsored by University Hospital Tübingen. Primary endpoint: Safety (Phase I). Started Mar 2021; status: completed.
02
Drugs
CoVac-1
03
Conditions
coronavirus disease 2019 (COVID-19)B cell deficiency
Beyond the preview
Go deeper on 2021-001070-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001070-38.